CJ, RaQualia deal

RaQualia granted CJ Group exclusive rights to develop, manufacture and commercialize RaQualia's RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia. RaQualia will receive an upfront payment and is eligible for developmental milestones and royalties. The serotonin (5-HT4) receptor partial agonist is in preclinical development to treat functional dyspepsia (FD) and other gastrointestinal motility disorders, including chronic constipation. Terms were not disclosed. ...